ID   NZM042
AC   CVCL_D833
SY   NZM42
DR   BioSample; SAMN07624447
DR   BioSample; SAMN14558339
DR   cancercelllines; CVCL_D833
DR   CBA; CBA-1391
DR   Cosmic; 1660298
DR   DepMap; ACH-001986
DR   Wikidata; Q54931576
RX   PubMed=20041153;
RX   PubMed=22475322;
RX   PubMed=32567790;
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Doubling time: 70-80 hours (CBA=CBA-1391).
CC   HLA typing: A*03:01,11:01; B*07:02,45:01; C*06:02,07:02 (PubMed=32567790).
CC   Sequence variation: Mutation; HGNC; 7989; NRAS; Simple; p.Gln61Lys (c.181C>A); ClinVar=VCV000073058; Zygosity=Heterozygous (PubMed=32567790; CBA=CBA-1391).
CC   Sequence variation: Mutation; HGNC; 11730; TERT; Simple; c.1-146C>T (c.250C>T) (C250T); Zygosity=Unspecified; Note=In promoter (PubMed=32567790).
CC   Omics: Deep exome analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: Metastatic; Not specified.
ST   Source(s): CBA=CBA-1391; PubMed=32567790
ST   Amelogenin: X,Y
ST   CSF1PO: 9,12
ST   D13S317: 8,11
ST   D16S539: 9,11
ST   D18S51: 14,16
ST   D19S433: 15
ST   D21S11: 29,32.2
ST   D2S1338: 17,20
ST   D3S1358: 16,17
ST   D5S818: 12,13
ST   D7S820: 8,10
ST   D8S1179: 14
ST   FGA: 19,20
ST   Penta D: 13,15
ST   Penta E: 15,18
ST   TH01: 9,9.3
ST   TPOX: 8,11
ST   vWA: 16,18
DI   NCIt; C3224; Melanoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
OI   CVCL_S423 ! NZM048
SX   Male
AG   71Y
CA   Cancer cell line
DT   Created: 22-10-12; Last updated: 02-05-24; Version: 19
//
RX   PubMed=20041153; DOI=10.1371/journal.pone.0008461;
RA   Jeffs A.R., Glover A.C., Slobbe L.J., Wang L., He S.-J., Hazlett J.A.,
RA   Awasthi A., Woolley A.G., Marshall E.S., Joseph W.R., Print C.G.,
RA   Baguley B.C., Eccles M.R.;
RT   "A gene expression signature of invasive potential in metastatic
RT   melanoma cells.";
RL   PLoS ONE 4:E8461-E8461(2009).
//
RX   PubMed=22475322; DOI=10.1186/1471-2407-12-141;
RA   Kim J.E., Stones C.J., Joseph W.R., Leung E.Y., Finlay G.J.,
RA   Shelling A.N., Phillips W.A., Shepherd P.R., Baguley B.C.;
RT   "Comparison of growth factor signalling pathway utilisation in
RT   cultured normal melanocytes and melanoma cell lines.";
RL   BMC Cancer 12:141.1-141.10(2012).
//
RX   PubMed=32567790; DOI=10.1111/pcmr.12908;
RA   Tran K.B., Gimenez G., Tsai P., Kolekar S., Rodger E.J.,
RA   Chatterjee A., Jabed A., Shih J.-H., Joseph W.R., Marshall E.S.,
RA   Wang Q., Print C.G., Eccles M.R., Baguley B.C., Shepherd P.R.;
RT   "Genomic and signalling pathway characterization of the NZM panel of
RT   melanoma cell lines: a valuable model for studying the impact of
RT   genetic diversity in melanoma.";
RL   Pigment Cell Melanoma Res. 34:136-143(2021).
//